Qin Maorong, Xu Kun, Chen Zhuo, Wen Xiaojie, Tang Yifu, Gao Yangyu, Zhang Hao, Ma Xingming
School of Health Management, Xihua University, Chengdu 610039, China.
Xinqiao Stomatological Hospital Co., Ltd, Chengdu 610093, China.
Nutr Rev. 2025 Jul 1;83(7):e1406-e1420. doi: 10.1093/nutrit/nuae154.
Vitamin C has been used as an essential antioxidant to reduce the inflammatory response associated with pneumonia and acute respiratory distress syndrome in patients with the 2019 coronavirus disease (COVID-19), but its effect on clinical outcomes remains controversial and inconclusive.
The purpose of this study was to conduct a meta-analysis and systematic review to assess the effects of vitamin C supplementation on the severity of COVID-19 in hospitalized patients.
Web of Science, Embase, Cochrane Library, PubMed, CNKI, CSTJ, Wan fang, and CBM databases were searched for publications between January 2020 and December 2023 that met the inclusion criteria.
The meta-analyses of outcomes in more than one study were performed using Review Manager software. Heterogeneity was evaluated using the I2 statistic. A randomized controlled trial, cohort studies, and retrospective studies in which vitamin C supplementation was supplemented as monotherapy or in combination, compared with placebo, no treatment, or other standard treatment without vitamin C were included.
After screening, 22 studies, with a total of 3429 patients, were selected for assessment. Odds ratios (ORs) with 95% CIs were calculated using fixed- and random-effects models. The meta-analysis showed significant effects of vitamin C on alleviating clinical outcomes in patients with COVID-19 (OR = 0.76, 95% CI = 0.65-0.89, P = .0007) but no shortening of the length of hospitalization (MD = 1.16, 95% CI = -0.13-2.44, P = .08) compared with the control group. Notably, vitamin C supplements significantly reduced the mortality risk (OR = 0.64, 95% CI = 0.51-0.80, P = .0001) and the incidence of severity (OR = 0.59, 95% CI = 0.43-0.80, P = .0006) in COVID-19 patients.
The findings suggest that vitamin C supplements may have a beneficial effect on clinical outcomes, as well as reducing severity and mortality in COVID-19 patients, but more clinical randomized controlled trials are needed to evaluate the role of vitamin C in treating COVID-19.
PROSPERO registration no. CRD42023491517.
维生素C已被用作一种重要的抗氧化剂,以减轻与2019冠状病毒病(COVID-19)患者的肺炎和急性呼吸窘迫综合征相关的炎症反应,但其对临床结局的影响仍存在争议且尚无定论。
本研究的目的是进行一项荟萃分析和系统评价,以评估补充维生素C对住院COVID-19患者病情严重程度的影响。
检索了Web of Science、Embase、Cochrane图书馆、PubMed、中国知网、维普资讯、万方和中国生物医学文献数据库,以查找2020年1月至2023年12月期间符合纳入标准的出版物。
使用Review Manager软件对一项以上研究的结局进行荟萃分析。使用I2统计量评估异质性。纳入以维生素C作为单一疗法或联合疗法补充,与安慰剂、不治疗或不含维生素C的其他标准治疗进行比较的随机对照试验、队列研究和回顾性研究。
筛选后,选择22项研究,共3429例患者进行评估。使用固定效应模型和随机效应模型计算95%置信区间的比值比(OR)。荟萃分析显示,维生素C对改善COVID-19患者的临床结局有显著效果(OR = 0.76,95%CI = 0.65 - 0.89,P = 0.0007),但与对照组相比,住院时间并未缩短(MD = 1.16,95%CI = -0.13 - 2.44,P = 0.08)。值得注意的是,维生素C补充剂显著降低了COVID-19患者的死亡风险(OR = 0.64,95%CI = 0.51 - 0.80,P = 0.0001)和重症发生率(OR = 0.59,95%CI = 0.43 - 0.80,P = 0.0006)。
研究结果表明,维生素C补充剂可能对临床结局有有益影响,同时降低COVID-19患者的严重程度和死亡率,但需要更多的临床随机对照试验来评估维生素C在治疗COVID-19中的作用。
PROSPERO注册号CRD42023491517。